(Reuters) - LONDON, July 31 - Shares in GlaxoSmithKline Plc
, Europe's biggest drugmaker, gained more than 3 percent
on Tuesday after a U.S. advisory panel recommended its diabetes
pill Avandia should stay on the market.
Even though data suggested Avandia may increase the risk of
a heart attack for some patients, panel members voted 22-1 to
keep the medicine on sale -- but most advisers backed stronger
warnings on the widely used drug.
Read more at Reuters.com Government Filings News
, Europe's biggest drugmaker, gained more than 3 percent
on Tuesday after a U.S. advisory panel recommended its diabetes
pill Avandia should stay on the market.
Even though data suggested Avandia may increase the risk of
a heart attack for some patients, panel members voted 22-1 to
keep the medicine on sale -- but most advisers backed stronger
warnings on the widely used drug.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment